CB-839 Got You Down? Our Company Has The Remedy

1B). A small fraction of patients received allogeneic HSCT after relapse (N?=?24), including 18 patients who were transplanted in CR2. First-line trial or anthracycline type had no significant impact on CR2 rate and post-relapse http://www.selleckchem.com/products/cb-839.html survival. Post-relapse outcome was not significantly different in the 12 patients who had HSCT in first CR (CR2 rate, 50% versus 31% and median post-relapse survival, 4.2 versus 6.8 months; P?=?0.21 and 0.97). The rate of patients achieving CR2 was 53, 80, 42.5, 17, and 0%, in patients treated with ICT, ICT?+?GO, GO, LDAC, and BSC, respectively (Table 3). Median post-relapse survival was 9, 19.8, 8.9, 5.6, and 3.2 months in these five subsets, respectively (Table 3). Interestingly, among those patients intensively treated, and despite small numbers, addition of GO to ICT was significantly associated with higher CR2 rate (P?=?0.02) and prolonged survival (P?=?0.04; Fig. 1C), with persistent trends when favorable CBF-AML were not considered (P?=?0.07 for both endpoints). In contrast, no differences in CR2 rate and survival were observed between patients treated with GO alone and those receiving http://www.selleck.cn/products/wnt-c59-c59.html ICT without added GO (Fig. 1C). Results of univariate analysis across the various salvage options are shown in Table 4. As shown, advanced age, shorter CR1 duration, higher WBC, unfavorable ECOG-PS, and non-favorable cytogenetics were associated with lower CR2 rate and shorter post-relapse survival. Interestingly, patients from the intermediate and adverse subgroup had similar CR2 rate or post-relapse survival. Furthermore, in patients with CN-AML, those with a favorable genotype had similar outcome than those without favorable genotype. In the subset of 173 patients assessed for gene mutations at diagnosis, FLT3-ITD was the single one associated with worse post-relapse survival, despite comparable CR2 rates (Table 4). Due to the rarity of patients with CBF-AML and their much better outcome, we excluded them from further analyses. In a multivariate analysis performed in patients http://www.selleckchem.com/products/BI6727-Volasertib.html with either intermediate or adverse karyotype, CR1 duration less than 12 months (HR, 1.8; P?